MICROBIOME PROBIOTICS SERIES: EUROPE

CONFIRMED PROBIOTICS SPEAKERSHIMANSHU KUMARHERMIE HARMSENROB BEUDEKER (Chair)JAN PETER VANPIJKERENFIONA CRISPIECAROLINE KURTZKIERAN TUOHYYEMI ADESOKANSenior Scientist, DanoneNutricia Research, TheNetherlandsAssociate Professor, Departmentof Medical Microbiology,University Medical CenterGroningen, The NetherlandsInvestment Director, DSMVenturingTechnologist, Teagasc FoodResearch Centre and APCMicrobiome IrelandAssistant Professor, FoodScience, University ofWisconsin – Madison, USAGroup Leader, Nutrition andNutrigenomics, FondazioneEdmund Mach, ItalyCSO, Gnubiotics Sciences SASenior Vice President andHead of Metabolic Programs,Synlogic Inc., USARANJAN KOIRALADepartment of Food, Environmental andNutritional Sciences (DeFENS), University ofMilan, ItalyCONFIRMED SKIN SPEAKERSBERNHARD PAETZOLDLIONEL BRETONERIC HUANGAUDREY GUENICHECo-Founder & Chief ScientificOfficer, S-Biomedic, SpainChair Professor, NationalCentral University, Taiwan;Adjunct Professor, Departmentof Dermatology, University ofCalifornia, San Diego, USAJULIE O’SULLIVANPhD Student, APC MicrobiomeIreland, Teagasc FoodResearch Centre, IrelandJACOB BAK HOLMPAUL FORSYTHEScientific Director, L'OréalAdvanced Research, FranceAssistant Professor, FirestoneInstitute for Respiratory Healthand Brain-Body Institute,McMaster University, CanadaMAYA IVANJESKUSenior Clinical Expert,Advanced Research, L’OréalResearch & Innovation, FranceChief Scientific Officer –LaFlore Probiotic Skincare,USAINGMAR CLAESChief Scientific OfficerYun (Probiotherapy) NV,BelgiumIVANA HALUSKOVABALTERIndependent consultant,Science for health partnershipand preventive medicine,French Society of ImmunologyKRISTIN NEUMANNAuthor & Founder,MyMicrobiomeDirector of ScientificOperations, ClinicalMicrobiomicsBJÖRN ANDERSSONProfessor, Department ofCell and Molecular Biology,Karolinska Institute, SwedenMARIE DRAGOMARCELLINE GOYENFounder, Gallinée, UK(Chair)Skin Therapist & GutTherapist, Editor for NTVH, TheNetherlandsCATHERINE O’NEILLCEO ANDBiopharma / KoppertBiologicalsELSA JUNGMANFounder and CEO,ELSI Skin HealthProfessor of TranslationDermatology, Universityof Manchester and CEO,SkinBiotherapeutics plc, UKTODD KRUEGERPETER JENSJOHANNA GILLBRORICHARD ANDREWSPresident and CEO, AOBiomeTherapeutics, USACo-founder and Chief ScientificOfficer, Skinome Research AB,SwedenPresident and CEO, Azitra Inc.,USAALEXANDER BUKOTOM VERLINDENGUUS KORTMANScientist Microbiomics, NIZO,The NetherlandsANNELEENCORNELISSENHead of Microbiology,Lysando AG, GermanyVice President for PreClinical and Clinical Researchand Development, HumanMetabolome TechnologiesCEO, Yun (Probiotherapy) NV,BelgiumHIMANSHU KUMARSenior Scientist, DanoneNutricia Research, TheNetherlandsSTEFANIA ARIOLIPost-Doctoral Researcher, Department ofFood Environmental and Nutritional Sciences,University of MilanMICROBIOME AND PROBIOTICS SERIES: EUROPE 2019

CONGRESS SCHEDULE08:00-09:00Room: Shipping HallDAY 1 MONDAY 20TH MAY 2019Registration & RefreshmentsRoom: Diamond Room I&IIRoom: Penn Room I&IIRoom: Mees AuditoriumMICROBIOME R&D AND BUSINESS COLLABORATION FORUMPROBIOTICS CONGRESSSKIN MICROBIOME & COSMECEUTICALS CONGRESSGlobal Engage Welcome Address and Morning Chair’s OpeningRemarks: Christophe Lacroix, Professor, Laboratory of FoodBiotechnology, Department of Health Sciences and Technology, ETHZürich, SwitzerlandGlobal Engage Welcome Address and Morning Chair’sOpening Remarks: Sylvie Morin, Director, Strategic BusinessDevelopment, LallemandKEYNOTE ADDRESS:KAREN NELSONKEYNOTE ADDRESS:CARINE BLANCHARDKEYNOTE ADDRESS:BRUNO POTKEYNOTE ADDRESS:DIRK HADRICHResearch Group of Industrial Microbiology andFood Biotechnology, Faculty of Sciences andBioengineering Sciences, Vrije UniversiteitBrussel, BelgiumShared responsibility for Industry, Regulators and Press: whatto do to get the consumer correctly informed on probiotics?The microbiota of the GIT participates actively in a tremendousnumber of live-critical processes and the inability to develop ormaintain a satisfactory microbiota is increasing the incidenceof chronic immune or metabolic dysfunctions later in live. Thepotential role of probiotics to positively impact this microbiota isbeing supported by numerous research observations, either in thelab or in the hospital. Numerous nutri-economic studies illustratethe positive impact probiotics may have on our society in termsof improving health and reducing healthcare costs. Still it is verydifficult to obtain a formal recognition of probiotic benefits, eitheras a food or as a drug. The confusion of the consumer thereforeMICROBIOME AND PROBIOTICS SERIES: EUROPE 2019Co-Founder & Chief Scientific OfficerS-Biomedic, SpainCutibacterium acnes the main componentof the skin microbiota C. acnes is the main bacterial component of the skin microbiomeon sebaceous and dry body sites (Byrd et al. 2018) Despite its dominant role on the skin many skin treatments aim ateradicating this bacterial species. I will present a selection examples of the literature why this bacteriais important to us and how it has a symbiontic relationship with itshuman host.KEYNOTE ADDRESS:ERIC HUANG09:35-10:1009:35-10:1009:35-10:10Policy and Programme Officer, HealthResearch, Personalised Medicine, DG Research& Innovation, European Commission, BelgiumThe collaborative efforts and researchdirections of European microbiome fundingEU has already funded 216 projects for more than 498 M topromote metagenomics and to advance our knowledge on microbes.MetaHIT as one of the first projects had a catalysing effect withits produced catalogue of gut microbes and the proposed distinct‘enterotypes’. Many more projects followed but we see today thatmechanisms, effects and causes are still not well understood so thatresearch is now gathering all kind of data to complement patientinformation aiming to advance health and disease management.Three new projects will start in 2019 to find applications and toenhance knowledge on the microbiome, host metabolism, nutrition,immune responses, lifestyle and other interplaying confounders. Theywill focus on cancer, liver failure and autism.R&D Specialist, Nestlé Research Center,SwitzerlandPrebiotic, probiotic, postbiotic: where do westand and how to move forward?Scientific evidence regarding the health benefits of prebiotic,probiotic and postbiotic supplementation have been mountingover the last five decades. However, consumer understanding ofthese discoveries has lagged behind, with interest rising in the lastdecade only. Despite clinically proven prebiotic effects with solublefibers, observed disease prevention following supplementation withspecific probiotic strains or the pre-clinical efficacy of microbialmetabolite supplementation, the gap between the clear scientificevidence and consumer engagement is visible. In this session, threeexamples of these scientific investigations (with a prebiotic, probioticand postbiotic respectively) will be discussed in the context ofcurrently available science, products and consumer messaging.KEYNOTE ADDRESS:BERNHARD , J. Craig Venter Institute, USATranslation of the Microbiome: are we there yetThe past 12 years has presented severalsignificant studies and observations on thehuman microbiome with great promise for new diagnostic andtherapeutics. Many new companies have been founded inthis field. Challenges that were evident in the earliest stagescontinue to plague the field. These include difficulties incomparing data sets from different studies; a focus on 16S geneanalysis; lack of gene expression studies; limited data on hostmicrobe interactions; and lack of global studies. The promisestill remains but as a community we need to figure out how toovercome these challenges in order to make the data from thehuman microbiome truly robust.Global Engage Welcome Address and Morning Chair’s OpeningRemarks: William Baird Commercial Director, Global EngageChair Professor, National Central University,Taiwan; Adjunct Professor, Department ofDermatology, University of California, SanDiego, USASkin Electro-biotic for microbiome bankingA commercial stool bank by collecting human gut microbiotais available in the market. Efforts from our group are devotedto establish a “Skin Microbiome Bank” for deveopment ofnovel skin probiotics and/or prebiotics. The microbes withina human microenvironment may compete with each other forthe same carbon source of fermentation. Microbiome editing bytargeting individual bacterial species in the microbiome usingbacteria-specific carbon source is our strategy to restore ahealth-associated microbiome after dysbiosis. The conjugatesof carbohydrates and polymers provide unique carbon sources(prebiotics) for specific skin probiotic bacteria. We demonstratefor the first time that skin bacteria can produce electricity via

CONGRESS SCHEDULEDAY 1 MONDAY 20TH MAY 2019Room: Mees AuditoriumEARLY LIFE DEVELOPMENT OF THE MICROBIOMEMICROBIOME & SKIN AILMENTSRoom: Shipping HallMorning Refreshments / One-to-One Meetings / Even Numbered Poster PresentationsEARLY LIFE DEVELOPMENT OF THE MICROBIOMEMICROBIOME & SKIN AILMENTSRoom: Diamond Room I&IIRoom: Penn Room I&IIRoom: Mees AuditoriumADAM BAKERHead of Discovery - Microbiome and HumanHealth, Chr. Hansen, DenmarkInnovating in probiotics during themicrobiome era. From screening toclinical development Screening in vitro and ex vivo to elucidate mechanisms ofmicrobe-host interaction. The microbiome as a source of probiotics and live bacterialtherapeutics Scientific and technical challenges in developing nextgeneration probioticsMICROBIOME AND PROBIOTICS SERIES: EUROPE 2019ASSAF ORON11:50-12:15 Assistant Professor, Head of the MicrobiomeResearch Lab, Azrieli Faculty of Medicine, Bar-IlanUniversity, IsraelA microbiome is born: changes to the gutmicrobiome in pregnancy and infancyPregnancy progression is associated with dramatic alterations inthe composition of the gut microbiota.The gut microbiota of pregnant women is characterized witha decrease in bacterial diversity which is accompanied by anincrease in “between sample” diversity and an increase in therelative abundance of Proteobacteria and opportunistic pathogens.Germfree mice inoculated with gut microbiota from pregnantwomen presented metabolic changes mirroring those of thepregnant women.We are now at the point of trying to understand whether thesechanges in community structure are a cause or consequence ofsome of the characteristics of pregnancy.11:50-12:1511:50-12:15 Vice President for Pre-Clinical and Clinical Research andDevelopment, Human Metabolome TechnologiesNovel Technologies for Understanding MetabolomicCommunications between Host and Microbiota Capillary Electrophoresis Mass Spectrometry (CE-MS) offers higher resolutionthan LC-MS. CE-MS measures greater number of SCFAs and resolves branched and unbranched SCFAs tomeasure enzymatic specificity. HMT provides an extra-large metabolomic space that can be connected to 16S rRNA sequencingfor understanding microbiota pathways.EARLY LIFE DEVELOPMENT OF THE MICROBIOMEOMRY KOREN ALEXANDER BUKO10:10-10:4010:10-10:40Researcher Integrative Medicine & Health, Louis BolkInstituut, The NetherlandsParticipatory evaluation of probiotics use for antibiotic-associated diarrhea innursing homes The introduction of probiotics Ecologic AAD reduced antibiotics associateddiarrhea by 16% in a Dutch elderly care institute. Participatory evaluation following implementation is a successful strategy for gaining insightsin the effects of probiotics in daily elderly care practice. A process evaluation resulted in useful insights in facilitators and barriers to theimplementation process. the bacterial fermentation. In this talk, the concept of probioticprebiotic-postbiotic-“electrobiotic" will be highlighted. Nextgeneration sequencing (NGS), although it is a new approachto biomarker identification, may not be able to dynamicallydetect the dysbiotic microbiome. We here demonstrate you thetechnology of ”electrobiotic” for profiling and monitoring the skindysbiosis in real time.Room: Diamond Room I&IIHERMAN VAN -10:10Continuedremains high and contradictory reports in the media (both regularand social) make it very difficult for them to understand thebenefits and limits of probiotics. Industry should keep investingin high quality research, regulators should define feasible criteriaallowing recognition of these research efforts, and media shouldcommunicate in a realistic, non-skewed and balanced way on thisresearch. Using a few recent examples the importance of eachstakeholder involved will be illustrated.Chief Business Officer, BiomX, IsraelNovel topical phage therapy for treating acneBX001 is a topical gel of a phage cocktailcomprised of natural phage capable oferadicating P. acnes, a main cause for acnedisease. BX001 has demonstrated high efficacy in eradicationof antibiotic resistant P. acnes strains and breakdown ofbiofilm. Under this talk we will share results from pre-clinicaldevelopment activities and challenges in manufacturing andformulation towards entry into clinical trials expected H1 2019.

CONGRESS SCHEDULEDAY 1 MONDAY 20TH MAY 2019LESLEY HOYLESYEMI ADESOKAN12:15-12:40EARLY CAREER RESEARCHERPRESENTATION:KATARZYNA HOOKSMICROBIOME AND PROBIOTICS SERIES: EUROPE 201912:40-12:55Research Associate KU Leuven and University ofAntwerp, Belgium; and Founder of Microbiomeinsights and Probiotics ConsultancyLactobacillus rhamnosus GR-1 - the best studied vaginalprobiotic strainLactobacillus rhamnosus GR-1 (LGR-1), originally isolatedfrom a female urethra, is one of the most widely used probioticstrains. Various health effects are well documented withthe best-known use in the treatment of bacterial vaginosis.Recently the complete genome sequence of LGR-1 wasdetermined and compared to L. rhamnosus GG and L.rhamnosus LC705 at the genomic and phenotypic level. A keydifference is an absence in LGR-1 of the spaCBA locus requiredfor pili-mediated intestinal epithelial adhesion. The LGR-1genome contains a unique cluster for EPS production, whichsynthesize glucose-rich, rhamnose-lacking molecules. Onlyfew cell-wall molecules were yet identified as essential factorsgoverning host-microbe interactions. Such an example is theLGR-1 lectin-like protein 1 involved in tissue tropism-mediatedadhesion to vaginal epithelial cells and immunomodulation.Chief Scientific Officer, Yun (Probiotherapy)NV, BelgiumThe use of ‘live’ beneficial lactobacilli totreat skin conditionsYUN is a Belgian biotech company thatsucceeded in building an innovative and unique R&D platformand technology, allowing to keep bacteria alive in water-basedenvironments. Use of live beneficial lactobacilli provides anantibiotics alternative by impacting the skin microbiome.Specifically for acne vulgaris YUN developed a formulation withmicroencapsulated live bacteria for the treatment of acne. Besidesthe impact on the skin microbiome and reduction of specific skinpathobionts linked with acne vulgaris, clinical symptoms of allpatients with mild to moderate acne improved in our clinical trial.The improvement in clinical symptoms of acne is further underlinedby a post-market follow up study. With our current data, YUNbelieves this will initiate a new era of skin therapeutics based onmicrobiome modulation, and provides a new therapeutic option toreduce antibiotic use for common skin conditions, like acne.EARLY CAREER RESEARCHERPRESENTATION:JULIE O’SULLIVANEARLY CAREER RESEARCHERPRESENTATION:MARIYA PETROVA12:40-12:5512:40-12:55Postdoctoral researcher; LaBRI / CNRS,University of Bordeaux, FranceChallenges of collaborative interdisciplinarymicrobiome projectsMicrobiota studies rely on metagenomic sequencing and arehighly technology-driven, thus require heavy bioinformaticssupport. Incorporating patient samples adds another layer ofcomplexity. Clinical microbiomics is best approached throughconsortia involving multiple specialities, including medicaldoctors, microbiologists and bioinformaticians. Opportunities toform such interdisciplinary collaborations among scientists andclinicians are becoming more frequent, as funding agencies andresearch institutions are both actively encouraging them. I willdiscuss the challenges we faced in Bordeaux during collaborativework between researchers and doctors interested in the intestinalmicrobiota of cystic fibrosis patients. I will introduce the scientificand practical context of the study, the difficulties and thestrategies that were adopted to progress the project, and the finalresults. Upon termination of the study, the benefits and pitfalls ofthe collaboration were clear, and this has allowed us to generaterecommendations for other teams attempting to initiate clinicalmicrobiome projects.INGMAR CLAESCSO, Gnubiotics Sciences SASelective Microbiome Modulation byMicrobiota Accessible Carbohydrates Tools for monitoring efficacy12:15-12:4012:15-12:40Associate Professor in MicrobiologyNottingham Trent University, UKUnderstanding the role of the gut microbiomein non-alcoholic fatty liver diseaseNon-alcoholic fatty liver disease (NAFLD) isthe most common cause of chronic liver disease worldwide, withincident rates of 20–30 % in western countries and 5–18 % inAsia and closely linked to the global obesity epidemic. Recentwork has shown perturbation of the microbiome and specificmicrobiome-associated metabolites contribute to the phenotypeof NAFLD. This talk will present findings from recent integratedsystems biology studies examining the role of the microbiome inNAFLD, highlighting potential new biomarkers for the diseaseand areas that require further study.PhD Student, APC Microbiome Ireland,Teagasc Food Research Centre, IrelandAntimicrobial potential of the skin microbiomeThe human skin microbiome naturally harbours hundreds ofdiverse bacterial species which represent part of the body’sfirst line of defence against the outside world. This commensalmicrobiota contributes to host health and is thought to beinvolved in the protection of the host against a range ofinfections. In this respect, the production of antimicrobialcompounds is likely to be one of the defence mechanisms ofthe host microbiota. With the increase in antibiotic resistance,alternative antimicrobial therapies such as bacteriocins arebeing investigated. This study was undertaken to isolate andcharacterise novel bacteriocin-producing bacteria populating thehuman skin surface.

CONGRESS SCHEDULEDAY 1 MONDAY 20TH MAY 2019Room: Diamond Room I&IIRoom: Mees AuditoriumJACOB BAK HOLMARNE MATERNA13:25-14:25Room: Ship

University of Florida, USA CAROLINE KURTZ Senior Vice President and Head of Metabolic Programs, Synlogic Inc., USA KOEN VENEMA Professor of Gut Microbiology, Centre for Healthy Eating & Food Innovation, Maastricht University – campus Venlo, The Netherlands OLAF LARSEN Science Manager, Ya